News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Videos|November 10, 2022

Approach to Treating Female Patients With Insomnia

Author(s)Charlene Gamadelo, MD

Charlene Gamadelo, MD, provides an overview of commonly utilized insomnia treatment modalities in the treatment of female patients with insomnia.

Episodes in this series

EP. 1 Overview of Insomnia

EP. 1 Overview of Insomnia

EP. 2 Insomnia in Female Patients

EP. 2 Insomnia in Female Patients

EP. 3 Quality of Life and Patient Communication Regarding Insomnia

EP. 3 Quality of Life and Patient Communication Regarding Insomnia

EP. 4 Managing Female Patients With Insomnia

EP. 4 Managing Female Patients With Insomnia

EP. 5 Approach to Treating Female Patients With Insomnia

EP. 5 Approach to Treating Female Patients With Insomnia

EP. 6 Challenges Associated With Insomnia Treatments

EP. 6 Challenges Associated With Insomnia Treatments

EP. 7 Insomnia Treatment: DORAs

EP. 7 Insomnia Treatment: DORAs

EP. 8 Insomnia Treatment Selection: DORA

EP. 8 Insomnia Treatment Selection: DORA

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

1 expert is featured in this series.

Comparing Elinzanetant with Current Options for VMS and Sleep Management

ByFiona C. Baker, PhD

December 8th 2025

1 expert is featured in this series.

Integrating Patient Reported Outcomes to Capture Meaningful Clinical Benefit

ByFiona C. Baker, PhD

December 8th 2025

1 expert is featured in this series.

NIRVANA Study Findings on Early Onset of VMS and Sleep Relief

ByFiona C. Baker, PhD

December 1st 2025

1 expert is featured in this series.

The NIRVANA Study’s Focus on VMS and Sleep Improvement

ByFiona C. Baker, PhD

December 1st 2025

1 expert is featured in this series.

Understanding Elinzanetant’s Impact on VMS and Sleep Health

ByFiona C. Baker, PhD

November 25th 2025

Latest CME

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Rachel N. Grisham, MD; Domenica Lorusso, MD, PhD

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

Trending on Contemporary OB/GYN

DARE to PLAY sildenafil cream becomes commercially available for women in select states

FDA approves gepotidacin (Blujepa) oral therapy for uncomplicated urogenital gonorrhea

Early ultrasound linked to improved fetal anomaly detection

Maternal GBS vaccine (GBS-AlpN) shows immunogenicity and acceptable safety in phase 2 trial

© 2025 MJH Life Sciences^®

All rights reserved.